卡培他滨联合胸腺肽在老年晚期胃癌的疗效及安全性分析

The curative effect and security analyzing of elderly late stage gastric cancer by Capecitabine combined with Thymic peptide

目的探讨卡培他滨联合胸腺肽在老年晚期胃癌的疗效及安全性情况。方法选取2014年2月~2016年2月我院收治的64例老年晚期胃癌患者临床资料,依据治疗措施的不同将其分为治疗A组(卡培他滨治疗组)和治疗B组(卡培他滨、胸腺肽治疗组),每组32例。比较两组患者近期疗效、远期疗效和不良反应的情况。结果治疗B组患者的总缓解率高于治疗A组,治疗B组老年晚期胃癌患者的胃癌进展时间、患者生存时间均短于治疗A组,差异有统计学意义(P<0.05)。两组老年晚期胃癌患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论卡培他滨联合胸腺肽治疗老年晚期胃癌患者,近期疗效和远期疗效均较好,安全性较高,值得临床推广应用。

Objective To approach curative effect and security analyzing of elderly late stage gastric cancer by Capecitabine combined with Thymic Peptide.Methods Sixty-four elderly patients with advanced gastric cancer admitted to our hospital from February 2014 to February 2016 were divided into treatment group A(Capecitabine treatment group)and treatment group B(Capecitabine combined with Thymic Deptide treatment group),with 32 cases in each group.The short-term efficacy,long-term efficacy and adverse reactions were compared between the two groups.Results The total remission rate of elderly patients with advanced gastric cancer in group B was higher than that in group A,while the progression time and survival time of elderly patients with advanced gastric cancer in group B were shorter than those in group A(P<0.05),there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The elderly late stage gastric cancer patients by Capecitabine combined with Thymic Peptide treatment,short-term curative effect and long-term curative effect are good,security is high,it is worth to be used.